A Multicenter, Randomized, Open-Label, Parallel, Active-Comparator Trial to Determine the Efficacy, Safety, and Pharmacokinetics of Ibuprofen Injection in Pediatric Patients

Trial Profile

A Multicenter, Randomized, Open-Label, Parallel, Active-Comparator Trial to Determine the Efficacy, Safety, and Pharmacokinetics of Ibuprofen Injection in Pediatric Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Ibuprofen (Primary) ; Paracetamol
  • Indications Fever
  • Focus Therapeutic Use
  • Sponsors Cumberland Pharmaceuticals
  • Most Recent Events

    • 07 Feb 2017 According to Cumberland Pharmaceuticals media release, results were published in the British BMC Pediatrics Journal.
    • 23 Nov 2015 Primary endpoint 'Fever Reduction' has been met, according to a Cumberland Pharmaceuticals media release.
    • 23 Nov 2015 According to a Cumberland Pharmaceuticals media release, ibuprofen injection (Caldolor) has been approved for pediatric patients six months of age and older.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top